Evidence map›Paper›PMID 35025928›Full record

ArticlePloS one2022

Evolutionary paths to macrolide resistance in a Neisseria commensal converge on ribosomal genes through short sequence duplications.

Jordan C Raisman, Michael A Fiore, Lucille Tomin, Joseph K O Adjei, Virginia X Aswad, Jonathan Chu, Christina J Domondon, Ben A Donahue, Claudia A Masciotti, Connor G McGrath and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. CommensalAnnual review of microbiology · 2025
    Review
  2. Article
  3. Article
  4. bioRxiv : the preprint server for biology · 2024
    Article
  5. The Prevalence of Antibiotic Tolerance inPathogens (Basel, Switzerland) · 2024
    Article
  6. Rolling the evolutionary dice:Microbiology spectrum · 2024
    Article
  7. Co-infection withJournal of otology · 2024
    Article
  8. Article
  9. Tolerance to Ceftriaxone inAntibiotics (Basel, Switzerland) · 2022
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Jordan C RaismanRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Michael A FioreRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Lucille TominRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Joseph K O AdjeiRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.ORCID 0000-0003-3402-7781
Virginia X AswadRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Jonathan ChuRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Christina J DomondonRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Ben A DonahueRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Claudia A MasciottiRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Connor G McGrathRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Jo MelitaRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Paul A PodbielskiRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Madelyn R SchreinerRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Lauren J TrumporeRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Peter C WengertRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
Emalee A WrightstoneRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.
André O HudsonRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.ORCID 0000-0001-5690-4322
Crista B WadsworthRochester Institute of Technology, Thomas H. Gosnell School of Life Sciences, Rochester, NY, United States of America.ORCID 0000-0002-9449-2418
Rochester Institute of Technology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neisseria commensals are an indisputable source of resistance for their pathogenic relatives. However, the evolutionary paths commensal species take to reduced susceptibility in this genus have been relatively underexplored. Here, we leverage in vitro selection as a powerful screen to identify the genetic adaptations that produce azithromycin resistance (≥ 2 μg/mL) in the Neisseria commensal, N. elongata. Across multiple lineages (n = 7/16), we find mutations that reduce susceptibility to azithromycin converge on the locus encoding the 50S ribosomal L34 protein (rpmH) and the intergenic region proximal to the 30S ribosomal S3 protein (rpsC) through short tandem duplication events. Interestingly, one of the laboratory evolved mutations in rpmH is identical (7LKRTYQ12), and two nearly identical, to those recently reported to contribute to high-level azithromycin resistance in N. gonorrhoeae. Transformations into the ancestral N. elongata lineage confirmed the causality of both rpmH and rpsC mutations. Though most lineages inheriting duplications suffered in vitro fitness costs, one variant showed no growth defect, suggesting the possibility that it may be sustained in natural populations. Ultimately, studies like this will be critical for predicting commensal alleles that could rapidly disseminate into pathogen populations via allelic exchange across recombinogenic microbial genera.

Indexed as

Anti-Bacterial AgentsAzithromycinDrug Resistance, BacterialMacrolidesMicrobial Sensitivity TestsMicrobiotaNeisseriaProtein Synthesis InhibitorsRibosomal ProteinsRibosomesRibosome Subunits, Large, BacterialRibosome Subunits, Small, BacterialRNA, Ribosomal, 23SSequence DeletionAnti-Bacterial AgentsAzithromycinMacrolidesProtein Synthesis Inhibitorsribosomal protein L34Ribosomal Proteinsribosomal protein S3ribosomal protein S30RNA, Ribosomal, 23S

Identifiers

PMID35025928
PMCPMC8758062
OpenAlexW4206689098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.